Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma

NCT03902184 is registered in ClinicalTrials.gov with Innate Pharma as lead sponsor.

NCT NCT03902184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03902184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma
Lead sponsor
Innate Pharma
Phase
Phase 2
Overall status
Completed
Start date
May 22, 2019
Completion date
January 8, 2026
Enrollment
170 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, t-cell, lymphoma, t-cell, cutaneous, mycosis fungoides/sezary syndrome